ClinicalTrials.Veeva

Menu

Prenatal Carrier Screening for Spinal Muscular Atrophy Among Thai Pregnant Women

M

Mahidol University

Status

Unknown

Conditions

Spinal Muscular Atrophy

Study type

Observational

Funder types

Other

Identifiers

NCT04859179
COA. MURA2020/1420

Details and patient eligibility

About

Spinal muscular atrophy (SMA) prenatal carrier screening is recommended by American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG). However, in Thailand, there are no standard protocol for SMA prenatal carrier screening.

Full description

Spinal muscular atrophy (SMA) is one of the most common neuromuscular autosomal recessive disorders. The incidence is about 1:10,000 livebirths. There are 5 subgroups base on onset of symptoms and clinical severity. Type 1 is the most severe type which age of onset is 6 months old and life expectancy is less than 1-2 years. SMA carrier frequency is approximately 1/40-1/60. Molecular genetic testing to detect copies number of SMN1 gene is possible with as high as 95% detection rate. Since 2008, American College of Medical Genetics (ACMG) and American College of Obstetrics and Gynecology (ACOG) recommended SMA preconceptional and prenatal carrier screening in general population. In Thailand, there are no standard protocol for SMA prenatal carrier screening.

Enrollment

200 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Maternal age > 18 years
  • Singleton pregnancy
  • Gestational age ≤ 14 weeks

Exclusion criteria

  • Refuse to participate the research trial

Trial contacts and locations

1

Loading...

Central trial contact

Takol Chareonsirisuthigul; Chayada Tangshewinsirikul

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems